The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Advances in pamrevlumab for pancreatic cancer treatment
Pamrevlumab, a humanized monoclonal antibody targeting connective tissue growth factor (CTGF), plays a crucial role in modulating tumor-stroma interactions in pancreatic cancer. Vincent Picozzi, MD, Virginia Mason Medical Center, Seattle, WA, describes earlier preclinical studies which demonstrate pamrevlumab’s potential to inhibit cancer cell growth in both cell lines and genetically engineered mouse models. Further research showed promise when combined with gemcitabine and nab-paclitaxel, suggesting an increased likelihood of surgical resection in patients with locally advanced pancreatic cancer. These findings provided foundations for an arm of the ongoing Precision Promise trial (NCT04229004) evaluating multiple experimental treatments, including pamrevlumab, in patients with metastatic pancreatic cancer. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
